

01-29-01

A

GRAYCARY TECHNOLOGY'S LEGAL EDGESM

4365 Executive Drive, Suite 1600
 San Diego, CA 92121-2189
 www.graycary.com
 O) 858-677-1456
 F) 858-677-1465

EXPRESS MAIL number: EL617037686USDate of Deposit: January 26, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "EXPRESS MAIL Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to BOX PATENT APPLICATION, Commissioner of Patents and Trademarks, Washington, DC 20231.

Yinia Naya
 (Name of person mailing paper)

[Signature]
 (Signature of person mailing paper)

JC929 U.S. PTO
09/771357
 01/26/01

ATTORNEY DOCKET NO. JHU1630

ATTN: BOX PATENT APPLICATION
COMMISSIONER OF PATENTS
 Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the new utility patent application of:

APPLICANTS: Saraswati Sukumar, Ella Evron, William C. Dooley, and
 Nancy Davidson

TITLE: ABERRANTLY METHYLATED GENES AS MARKERS
 OF BREAST MALIGNANCY

Enclosed are the following papers, including all those required to receive a filing date under
 37 CFR § 1.53(b):

Number of Pages

Specification	67
Claims	5
Abstract	1
Declaration – Unsigned	4
Drawings – Formal	22

ATTN: BOX PATENT APPLICATION

In re Application of:

Sukumar, et al.

Filed: January 26, 2001

Page 2

PATENT
Attorney Docket No.: JHU1630

Enclosures:

- Request and Certification Under 35 U.S.C. 122(b)(2)(B)(i); and
- Return Postcard.

The filing fee has been calculated as shown below:

	Number Filed		Number Extra		Rate			Fee	
					Large Entity	Small Entity		Small Entity	Large Entity
Total Claims	37	=		X	\$18	\$09	=	\$.00	\$.00
Independent Claims	4	=		X	\$80	\$40	=	\$.00	\$.00
Multiple Dependent Claims Presented: ___ Yes <u>X</u> No					\$270	\$135			\$.00
					BASIC FEE			\$710.00	\$355.00
					TOTAL FEE			\$.00	\$.00

The payment of the filing fee is to be deferred until the executed Declaration is filed.
Do not charge our deposit account. However, please charge any other fees other
than the filing fee that may be due or any credits to Deposit Account No.: 50-1355.

If this application is found to be INCOMPLETE, or if a telephone conference would
otherwise be helpful, please call the undersigned at (858) 677-1456.

ATTN: BOX PATENT APPLICATION

In re Application of:

Sukumar, et al.

Filed: January 26, 2001

Page 3

PATENT

Attorney Docket No.: JHU1630

All future correspondence should be addressed to:

Lisa A. Haile, J.D., Ph.D.
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189
(858) 677-1456

A duplicate copy of this letter is enclosed. Kindly acknowledge receipt of this application by returning the enclosed postcard.

Respectfully submitted,

GRAY CARY WARE & FREIDENRICH LLP



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347

January 26, 2001

Date

Enclosures

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)		First Named Inventor	Saraswati Sukumar
		Title	ABERRANTLY METHYLATED GENES AS MARKERS OF BREAST MALIGNANCY
		Atty Docket Number	JHU1630

09/771357
01/26/01
c929 U.S. PTO

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

January 26, 2001

Date

Lisa A. Haile
Signature

Lisa A. Haile, J.D., Ph.D.

Type or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.